Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Vesterbacka

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Scandinavian Journal of Infectious Diseases|January 9, 2013
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trialLars-Magnus Andersson, Jan Vesterbacka, Anders Blaxhult, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 24, 2025
The effect of remdesivir and nirmatrelvir/ritonavir on mortality in patients hospitalized with COVID-19 during the Omicron era: an emulated target trialJohn Karlsson Valik, Pontus Hedberg, Piotr Nowak, et al.
Lakartidningen|October 6, 2020
Boris Kan, Marcus Ahl, Ola Blennow, et al.
Life Science Alliance|May 10, 2022
Genome-scale metabolic models for natural and long-term drug-induced viral control in HIV infectionAnoop T Ambikan, Sara Svensson-Akusjärvi, Shuba Krishnan, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 4, 2011
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patientsDaniel Röshammar, Ulrika S H Simonsson, Håkan Ekvall, et al.
European Journal of Clinical Pharmacology|December 8, 2009
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patientsFilip Josephson, Maria C H Andersson, Leo Flamholc, et al.
Scientific Reports|July 26, 2017
Richer gut microbiota with distinct metabolic profile in HIV infected Elite ControllersJan Vesterbacka, Javier Rivera, Kajsa Noyan, et al.
HIV Medicine|April 5, 2026
HIV-1 viral load and reservoir size remain stable following SARS-CoV-2 mRNA vaccination in people with HIVOscar Kieri, Bianca B Jütte, Jan Vesterbacka, et al.
Plos One|February 6, 2013
Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapyJan Vesterbacka, Piotr Nowak, Babilonia Barqasho, et al.
AIDS (London, England)|February 13, 2023
Role of myeloid cells in system-level immunometabolic dysregulation during prolonged successful HIV-1 treatmentSara Svensson Akusjärvi, Shuba Krishnan, Anoop T Ambikan, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Scandinavian Journal of Infectious Diseases|January 9, 2013
Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: an open-label randomized controlled trialLars-Magnus Andersson, Jan Vesterbacka, Anders Blaxhult, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|September 24, 2025
The effect of remdesivir and nirmatrelvir/ritonavir on mortality in patients hospitalized with COVID-19 during the Omicron era: an emulated target trialJohn Karlsson Valik, Pontus Hedberg, Piotr Nowak, et al.
Lakartidningen|October 6, 2020
Boris Kan, Marcus Ahl, Ola Blennow, et al.
Life Science Alliance|May 10, 2022
Genome-scale metabolic models for natural and long-term drug-induced viral control in HIV infectionAnoop T Ambikan, Sara Svensson-Akusjärvi, Shuba Krishnan, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 4, 2011
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patientsDaniel Röshammar, Ulrika S H Simonsson, Håkan Ekvall, et al.
European Journal of Clinical Pharmacology|December 8, 2009
The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patientsFilip Josephson, Maria C H Andersson, Leo Flamholc, et al.
Scientific Reports|July 26, 2017
Richer gut microbiota with distinct metabolic profile in HIV infected Elite ControllersJan Vesterbacka, Javier Rivera, Kajsa Noyan, et al.
HIV Medicine|April 5, 2026
HIV-1 viral load and reservoir size remain stable following SARS-CoV-2 mRNA vaccination in people with HIVOscar Kieri, Bianca B Jütte, Jan Vesterbacka, et al.
Plos One|February 6, 2013
Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapyJan Vesterbacka, Piotr Nowak, Babilonia Barqasho, et al.
AIDS (London, England)|February 13, 2023
Role of myeloid cells in system-level immunometabolic dysregulation during prolonged successful HIV-1 treatmentSara Svensson Akusjärvi, Shuba Krishnan, Anoop T Ambikan, et al.
Pageof 4